The Effectiveness of Ledipasvir/Sofosbuvir in the Treatment of Genotype 2 HCV

In a phase II study, a 12-week course — but not an 8-week course — of LDV/SOF achieved a sustained viral response of greater than 90% at 12 weeks post-treatment.

Ledipasvir/sofosbuvir (LDV/SOF) is currently FDA approved for the treatment of genotypes 1 and 4 hepatitis C virus (HCV). Its effectiveness in genotype 2 HCV-infected patients is unknown, since reduced in vitro activity of LDV against genotype 2 HCV has hindered large-scale studies in this population (about 13% of HCV-infected patients globally).

In this phase II, manufacturer-sponsored, open-label study, investigators evaluated the efficacy of LDV/SOF in genotype 2 HCV-infected patients at two centers in New Zealand. An initial cohort was to receive daily LDV/SOF for 12 weeks, and if at least 90% achieved a sustained viral response (SVR; HCV RNA <15 IU/mL) at 4 weeks after therapy, a second cohort was enrolled to receive 8 weeks of daily LD…

Reviewing Author

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

The Effectiveness of Ledipasvir/Sofosbuvir in the Treatment of Genotype 2 HCV

Topics

Reviewing Author